Univariable and multivariable analyses of factors associated with mortality of patients with COVID-19 receiving CAR T cells
| . | All patients . | Time between CAR T-cell therapy and COVID-19, mo . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤6 . | >6 . | |||||||||||
| Univariable . | Multivariable . | Univariable . | Univariable . | |||||||||
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Sex | ||||||||||||
| Female | — | — | — | — | — | — | — | — | — | — | — | — |
| Male | 2.682 | 0.849-8.474 | .093 | 2.742 | 0.848-8.861 | .092 | 4.897 | 0.591-40.604 | .141 | 1.928 | 0.417-8.908 | .401 |
| Age, y | ||||||||||||
| <50 | — | — | — | — | — | — | — | — | — | — | — | — |
| ≥50 | 5.119 | 0.673-38.955 | .115 | — | — | — | 1.809 | 0.222-14.742 | .580 | 42.159 | 0.068-26 050.639 | .254 |
| Comorbidities, n | ||||||||||||
| None | — | — | — | — | — | — | — | — | — | — | — | — |
| 1 | 3.093 | 0.772-12.393 | .111 | — | — | — | 3.093 | 0.772-12.393 | .111 | 3.438 | 0.482-24.537 | .218 |
| 2 | 3.021 | 0.498-18.328 | .229 | — | — | — | 3.021 | 0.498-18.328 | .229 | 2.055 | 0.185-22.871 | .558 |
| ≥3 | 1.880 | 0.413-8.562 | .414 | — | — | — | 1.880 | 0.413-8.562 | .414 | 6.111 | 0.820-45.529 | .077 |
| Malignancy status at COVID-19 diagnosis | ||||||||||||
| Controlled disease | — | — | — | — | — | — | — | — | — | — | — | — |
| Active disease | 2.707 | 0.931-7.870 | .067 | 2.652 | 0.907-7.754 | .075 | 2.707 | 0.931-7.870 | .944 | 1.121 | 0.133-9.446 | .916 |
| Unknown | 1.579 | 0.188-13.238 | .674 | 1.059 | 0.123-9.132 | .958 | — | — | .947 | — | — | — |
| CAR T-cell construct | ||||||||||||
| Axi-cel | — | — | — | — | — | — | — | — | — | — | — | — |
| Tisa-cel | 0.888 | 0.321-2.458 | .820 | — | — | — | 0.479 | 0.092-2.494 | .382 | 1.552 | 0.296-8.132 | .603 |
| Other | — | — | .986 | — | — | — | — | — | .991 | — | — | — |
| ICU stay | 1.529 | 0.554-4.225 | .413 | — | — | — | 0.887 | 0.211-3.729 | .870 | 3.331 | 0.643-17.247 | .152 |
| Tocilizumab/steroids after CAR T cells | 1.437 | 0.520-3.972 | .484 | — | — | — | ||||||
| Time from CAR T cells to COVID-19, mo | ||||||||||||
| ≤6 | — | — | — | — | — | — | ||||||
| >6 | 0.998 | 0.359-2.770 | .996 | — | — | — | ||||||
| Neutrophils at COVID-19 diagnosis, n per mm3 | ||||||||||||
| ≤500 | — | — | — | — | — | — | — | — | — | — | — | — |
| >500 | 0.611 | 0.161-2.321 | .469 | — | — | — | 0.761 | 0.167-3.472 | .724 | — | — | — |
| Lymphocytes at COVID-19 diagnosis, n per mm3 | ||||||||||||
| ≤200 | — | — | — | — | — | — | — | — | — | — | — | — |
| >200 | 0.551 | 0.164-1.846 | .334 | — | — | — | 0.568 | 0.133-2.419 | .444 | 0.872 | 0.089-8.511 | .907 |
| . | All patients . | Time between CAR T-cell therapy and COVID-19, mo . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤6 . | >6 . | |||||||||||
| Univariable . | Multivariable . | Univariable . | Univariable . | |||||||||
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Sex | ||||||||||||
| Female | — | — | — | — | — | — | — | — | — | — | — | — |
| Male | 2.682 | 0.849-8.474 | .093 | 2.742 | 0.848-8.861 | .092 | 4.897 | 0.591-40.604 | .141 | 1.928 | 0.417-8.908 | .401 |
| Age, y | ||||||||||||
| <50 | — | — | — | — | — | — | — | — | — | — | — | — |
| ≥50 | 5.119 | 0.673-38.955 | .115 | — | — | — | 1.809 | 0.222-14.742 | .580 | 42.159 | 0.068-26 050.639 | .254 |
| Comorbidities, n | ||||||||||||
| None | — | — | — | — | — | — | — | — | — | — | — | — |
| 1 | 3.093 | 0.772-12.393 | .111 | — | — | — | 3.093 | 0.772-12.393 | .111 | 3.438 | 0.482-24.537 | .218 |
| 2 | 3.021 | 0.498-18.328 | .229 | — | — | — | 3.021 | 0.498-18.328 | .229 | 2.055 | 0.185-22.871 | .558 |
| ≥3 | 1.880 | 0.413-8.562 | .414 | — | — | — | 1.880 | 0.413-8.562 | .414 | 6.111 | 0.820-45.529 | .077 |
| Malignancy status at COVID-19 diagnosis | ||||||||||||
| Controlled disease | — | — | — | — | — | — | — | — | — | — | — | — |
| Active disease | 2.707 | 0.931-7.870 | .067 | 2.652 | 0.907-7.754 | .075 | 2.707 | 0.931-7.870 | .944 | 1.121 | 0.133-9.446 | .916 |
| Unknown | 1.579 | 0.188-13.238 | .674 | 1.059 | 0.123-9.132 | .958 | — | — | .947 | — | — | — |
| CAR T-cell construct | ||||||||||||
| Axi-cel | — | — | — | — | — | — | — | — | — | — | — | — |
| Tisa-cel | 0.888 | 0.321-2.458 | .820 | — | — | — | 0.479 | 0.092-2.494 | .382 | 1.552 | 0.296-8.132 | .603 |
| Other | — | — | .986 | — | — | — | — | — | .991 | — | — | — |
| ICU stay | 1.529 | 0.554-4.225 | .413 | — | — | — | 0.887 | 0.211-3.729 | .870 | 3.331 | 0.643-17.247 | .152 |
| Tocilizumab/steroids after CAR T cells | 1.437 | 0.520-3.972 | .484 | — | — | — | ||||||
| Time from CAR T cells to COVID-19, mo | ||||||||||||
| ≤6 | — | — | — | — | — | — | ||||||
| >6 | 0.998 | 0.359-2.770 | .996 | — | — | — | ||||||
| Neutrophils at COVID-19 diagnosis, n per mm3 | ||||||||||||
| ≤500 | — | — | — | — | — | — | — | — | — | — | — | — |
| >500 | 0.611 | 0.161-2.321 | .469 | — | — | — | 0.761 | 0.167-3.472 | .724 | — | — | — |
| Lymphocytes at COVID-19 diagnosis, n per mm3 | ||||||||||||
| ≤200 | — | — | — | — | — | — | — | — | — | — | — | — |
| >200 | 0.551 | 0.164-1.846 | .334 | — | — | — | 0.568 | 0.133-2.419 | .444 | 0.872 | 0.089-8.511 | .907 |
Axi-cel, axicabtagene ciloleucel; CI, confidence interval; HR, hazard ratio; tisa-cel, tisagenlecleucel.